{
 "name": "健喬",
 "slug": "tw-4114",
 "aliases": [
  "健喬信元醫藥生技股份有限公司",
  "SYNMOSA",
  "4114"
 ],
 "ticker": "4114",
 "industry": "生技醫療業",
 "website": "http://www.synmosa.com.tw",
 "summary": "健喬（4114）是上櫃的生技醫療類股公司，1970 年成立，2003 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "健喬信元醫藥生技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "SYNMOSA",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2003-05-12",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "1970-08-25",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "林智暉",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "林智暉",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 5504296880,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "勤業眾信聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "http://www.synmosa.com.tw",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 746971,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": 38.69,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": 27.04,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O"
  },
  {
   "claim": "授權合作：QUVIVIQ（daridorexant）",
   "value": "Nxera Pharma Japan｜新加坡、泰國、印尼、馬來西亞、菲律賓、越南、澳洲及紐西蘭｜2026-10-14",
   "unit": "",
   "as_of": "2026-10-14",
   "source": "https://www.synmosa.com.tw/tw/NewsGallery/ugC_NewsGallery_Detail.asp?hidNewsGalleryCatID=1&hidNewsGalleryID=253",
   "note": "獨家授權、供應及商業化協議；內文公告日期2026-10-14，新聞列表上架標示2026-10-15。簽約金、里程碑金及權利金僅揭露付款類型，未揭露數額與比率。"
  },
  {
   "claim": "主要產品：Optune",
   "value": "膠質母細胞瘤｜再鼎合作引進之療法｜台灣",
   "unit": "",
   "as_of": "2026-01-05",
   "source": "https://www.synmosa.com.tw/tw/NewsGallery/ugC_NewsGallery_Detail.asp?hidNewsGalleryCatID=1&hidNewsGalleryID=237",
   "note": "公司新聞稿披露之產品與引進範圍；不等同完整藥證資料。"
  },
  {
   "claim": "主要產品：Qinlock",
   "value": "胃腸道基質瘤（GIST）｜再鼎合作引進之療法｜台灣",
   "unit": "",
   "as_of": "2026-01-05",
   "source": "https://www.synmosa.com.tw/tw/NewsGallery/ugC_NewsGallery_Detail.asp?hidNewsGalleryCatID=1&hidNewsGalleryID=237",
   "note": "公司新聞稿披露之產品與引進範圍；不等同完整藥證資料。"
  },
  {
   "claim": "主要產品：Augtyro",
   "value": "ROS1基因融合非小細胞肺癌（NSCLC）與NTRK基因融合實體腫瘤｜再鼎合作引進之療法｜台灣",
   "unit": "",
   "as_of": "2026-01-05",
   "source": "https://www.synmosa.com.tw/tw/NewsGallery/ugC_NewsGallery_Detail.asp?hidNewsGalleryCatID=1&hidNewsGalleryID=237",
   "note": "公司新聞稿披露之產品與引進範圍；不等同完整藥證資料。"
  },
  {
   "claim": "授權合作：Optune",
   "value": "再鼎台灣醫藥有限公司｜台灣｜2026-01-05",
   "unit": "",
   "as_of": "2026-01-05",
   "source": "https://www.synmosa.com.tw/tw/NewsGallery/ugC_NewsGallery_Detail.asp?hidNewsGalleryCatID=1&hidNewsGalleryID=237",
   "note": "公司2026-01-05宣布簽署六項療法獨家授權協議；當日MOPS亦確認正式簽署。金額與比率未揭露。"
  },
  {
   "claim": "授權合作：Qinlock",
   "value": "再鼎台灣醫藥有限公司｜台灣｜2026-01-05",
   "unit": "",
   "as_of": "2026-01-05",
   "source": "https://www.synmosa.com.tw/tw/NewsGallery/ugC_NewsGallery_Detail.asp?hidNewsGalleryCatID=1&hidNewsGalleryID=237",
   "note": "公司2026-01-05宣布簽署六項療法獨家授權協議；當日MOPS亦確認正式簽署。金額與比率未揭露。"
  },
  {
   "claim": "授權合作：Augtyro",
   "value": "再鼎台灣醫藥有限公司｜台灣｜2026-01-05",
   "unit": "",
   "as_of": "2026-01-05",
   "source": "https://www.synmosa.com.tw/tw/NewsGallery/ugC_NewsGallery_Detail.asp?hidNewsGalleryCatID=1&hidNewsGalleryID=237",
   "note": "公司2026-01-05宣布簽署六項療法獨家授權協議；當日MOPS亦確認正式簽署。金額與比率未揭露。"
  },
  {
   "claim": "授權合作：Tivdak",
   "value": "再鼎台灣醫藥有限公司｜台灣｜2026-01-05",
   "unit": "",
   "as_of": "2026-01-05",
   "source": "https://www.synmosa.com.tw/tw/NewsGallery/ugC_NewsGallery_Detail.asp?hidNewsGalleryCatID=1&hidNewsGalleryID=237",
   "note": "公司2026-01-05宣布簽署六項療法獨家授權協議；當日MOPS亦確認正式簽署。金額與比率未揭露。"
  },
  {
   "claim": "授權合作：Vyvgart",
   "value": "再鼎台灣醫藥有限公司｜台灣｜2026-01-05",
   "unit": "",
   "as_of": "2026-01-05",
   "source": "https://www.synmosa.com.tw/tw/NewsGallery/ugC_NewsGallery_Detail.asp?hidNewsGalleryCatID=1&hidNewsGalleryID=237",
   "note": "公司2026-01-05宣布簽署六項療法獨家授權協議；當日MOPS亦確認正式簽署。金額與比率未揭露。"
  },
  {
   "claim": "授權合作：Cobenfy",
   "value": "再鼎台灣醫藥有限公司｜台灣｜2026-01-05",
   "unit": "",
   "as_of": "2026-01-05",
   "source": "https://www.synmosa.com.tw/tw/NewsGallery/ugC_NewsGallery_Detail.asp?hidNewsGalleryCatID=1&hidNewsGalleryID=237",
   "note": "公司2026-01-05宣布簽署六項療法獨家授權協議；當日MOPS亦確認正式簽署。金額與比率未揭露。"
  },
  {
   "claim": "授權合作：Diovan（得安穩）",
   "value": "臺灣諾華（Novartis）｜台灣｜2026-05-13",
   "unit": "",
   "as_of": "2026-05-13",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?seq_no=1&spoke_time=190809&spoke_date=20260513&co_id=4114&TYPEK=otc&step=2&firstin=1",
   "note": "發言日期：2026-05-13 19:08:09；主旨：本公司與臺灣諾華公司(Novartis)簽訂藥物經銷合約。藥物經銷合約及醫療機構通路行銷推廣權；生效日2026-05-15。非研發或專利技術授權。"
  },
  {
   "claim": "授權合作：Co-Diovan（可得安穩）",
   "value": "臺灣諾華（Novartis）｜台灣｜2026-05-13",
   "unit": "",
   "as_of": "2026-05-13",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?seq_no=1&spoke_time=190809&spoke_date=20260513&co_id=4114&TYPEK=otc&step=2&firstin=1",
   "note": "發言日期：2026-05-13 19:08:09；主旨：本公司與臺灣諾華公司(Novartis)簽訂藥物經銷合約。藥物經銷合約及醫療機構通路行銷推廣權；生效日2026-05-15。非研發或專利技術授權。"
  },
  {
   "claim": "授權合作：Exforge HCT（力安穩）",
   "value": "臺灣諾華（Novartis）｜台灣｜2026-05-13",
   "unit": "",
   "as_of": "2026-05-13",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?seq_no=1&spoke_time=190809&spoke_date=20260513&co_id=4114&TYPEK=otc&step=2&firstin=1",
   "note": "發言日期：2026-05-13 19:08:09；主旨：本公司與臺灣諾華公司(Novartis)簽訂藥物經銷合約。藥物經銷合約及醫療機構通路行銷推廣權；生效日2026-05-15。非研發或專利技術授權。"
  },
  {
   "claim": "授權合作：Exforge（易安穩）",
   "value": "臺灣諾華（Novartis）｜台灣｜2026-05-13",
   "unit": "",
   "as_of": "2026-05-13",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?seq_no=1&spoke_time=190809&spoke_date=20260513&co_id=4114&TYPEK=otc&step=2&firstin=1",
   "note": "發言日期：2026-05-13 19:08:09；主旨：本公司與臺灣諾華公司(Novartis)簽訂藥物經銷合約。藥物經銷合約及醫療機構通路行銷推廣權；生效日2026-05-15。非研發或專利技術授權。"
  },
  {
   "claim": "授權合作：Eliquis（艾必克）",
   "value": "輝瑞大藥廠（Pfizer）｜台灣｜2026-06-01",
   "unit": "",
   "as_of": "2026-06-01",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?seq_no=1&spoke_time=181605&spoke_date=20260601&co_id=4114&TYPEK=otc&step=2&firstin=1",
   "note": "發言日期：2026-06-01 18:16:05；主旨：本公司與輝瑞大藥廠（Pfizer)簽訂藥物經銷合約。藥物經銷及行銷推廣權，非研發或專利技術授權。"
  }
 ],
 "provided_by": "public_sources",
 "verified_at": "2026-10-22",
 "url": "https://drugnews.com.tw/companies/tw-4114.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}